Sp646
MECHANISMS FOR THE CHANGING EPIDEMIOLOGY OF COLORECTAL CANCER: A BASIC/TRANSLATIONAL PERSPECTIVE
Date
May 7, 2023
Explore related products in the following collection:
Society: AGA
Increasing risk for early onset CRC under age 50 has been well established. More recent trends suggest that this risk is extending beyond age 50, potentially expanding the public health impact of the factors driving increased risk. This symposium will: 1) Review the changing epidemiology of colorectal cancer; 2) Review potential causes from epidemiologic and basic science perspectives; 3) Discuss implications of the changing epidemiology for basic/translational research, as well as clinical research and clinical practice.
Increasing risk for early onset CRC under age 50 has been well established. More recent trends suggest that this risk is extending beyond age 50, potentially expanding the public health impact of the factors driving increased risk. This symposium will: 1) Review the changing epidemiology of colorectal cancer; 2) Review potential causes from epidemiologic and basic science perspectives; 3) Discuss implications of the changing epidemiology for basic/translational research, as well as clinical research and clinical practice.
Presenter
University of Chicago
Tracks
Related Products
HABITUAL MEAT INTAKE IS ASSOCIATED WITH INCREASED RISK OF DISEASE FLARE IN ULCERATIVE COLITIS: INITIAL RESULTS FROM THE PREDICCT STUDY
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
DETERMINANTS OF INVASIVE SIGNET RING CELL CARCINOMA IN HEREDITARY DIFFUSE GASTRIC CANCER
BACKGROUND: Colonic polyposis, which is a risk factor for colorectal cancer (CRC), can be driven by a pathogenic variant in a polyposis gene. However, in many cases germline genetic testing is negative, leaving the cause of the polyposis unknown…
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
